Overall survival curve for patients with malignant peritoneal mesothelioma (MPM) treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Kaplan-Meier actuarial overall survival (OS) curve for 211 patients with malignant peritoneal mesothelioma (MPM) treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The median actuarial overall survival was 38.4 months; the actuarial 5 and 10-year survivals were 41 and 26 percent, respectively.

Reproduced from: Alexander HR Jr, Bartlett DL, Pingpank JF, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery 2013; 153:779. Illustration used with the permission of Elsevier Inc. All rights reserved.

Graphic 95960 Version 1.0

خرید پکیج

Overall survival curve for patients with malignant peritoneal mesothelioma (MPM) treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy